Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

AIDS primary central nervous system lymphoma

I W Flinn1, R F Ambinder

  • 1Johns Hopkins Oncology Center, Baltimore, MD 21231, USA.

Current Opinion in Oncology
|September 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Metabolic tumor volume predicts outcome in patients with advanced stage follicular lymphoma from the RELEVANCE trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2023
Same author

Pharmacokinetically-targeted dosed everolimus maintenance therapy in lymphoma patients.

Cancer chemotherapy and pharmacology·2017
Same author

Rituximab: a benchmark in the development of chemotherapy-free treatment strategies for follicular lymphomas.

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial.

Leukemia·2016
Same author

Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up.

Leukemia·2012
Same author

A novel isoform of the 8p22 tumor suppressor gene DLC1 suppresses tumor growth and is frequently silenced in multiple common tumors.

Oncogene·2011

Primary central nervous system lymphomas significantly increase in AIDS patients, linked to Epstein-Barr virus and severe immunocompromise. New diagnostic methods show promise for earlier detection in HIV infection.

Area of Science:

  • Neuro-oncology
  • Infectious Diseases
  • Immunology

Background:

  • Primary central nervous system lymphomas (PCNSLs) are B-cell malignancies with a dramatically increased incidence in AIDS patients.
  • These lymphomas are consistently associated with Epstein-Barr virus (EBV) and typically manifest late in HIV infection, correlating with severe immunocompromise.
  • Distinguishing PCNSLs from toxoplasmosis via standard radiography presents a diagnostic challenge.

Purpose of the Study:

  • To review the epidemiology, clinical presentation, and diagnostic challenges of PCNSLs in the context of HIV/AIDS.
  • To explore novel diagnostic modalities for PCNSLs in immunocompromised patients.
  • To discuss current and potential therapeutic strategies for PCNSLs in AIDS.

Main Methods:

  • Review of literature on PCNSLs in HIV/AIDS patients.

Related Experiment Videos

  • Discussion of diagnostic techniques including imaging (PET, SPECT) and molecular methods (PCR for EBV DNA).
  • Analysis of treatment outcomes and emerging therapeutic approaches.

    • Main Results:

    • PCNSLs show a several thousand-fold increase in incidence among AIDS patients, strongly linked to EBV.
    • EBV gene expression patterns indicate profound immune deficiency.
    • Promising noninvasive or minimally invasive diagnostic tools include PCR for EBV DNA in CSF, PET, and SPECT scans.
    • Median survival is very short, though occasional long remissions occur with therapy.

    Conclusions:

    • PCNSLs are a significant complication of advanced HIV/AIDS, characterized by EBV association and poor prognosis.
    • Advanced diagnostic techniques may reduce the need for brain biopsies.
    • Combined modality therapy, including chemotherapy, is under investigation for improved patient outcomes.